ENTRY       N00247                      Network
NAME        HGF-overexpression to PI3K signaling pathway
DEFINITION  HGF* -> MET -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD
  EXPANDED  3082v1 -> 4233 -> 2549 -> (5290,5291,5293) -> C05981 -> (207,208,10000) -| 572
CLASS       nt06214 PI3K signaling
            nt06263 Hepatocellular carcinoma
TYPE        Variant
PATHWAY     hsa05225  Hepatocellular carcinoma
DISEASE     H00048  Hepatocellular carcinoma
GENE        3082  HGF; hepatocyte growth factor
            4233  MET; MET proto-oncogene, receptor tyrosine kinase
            2549  GAB1; GRB2 associated binding protein 1
            5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
            5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
            5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
            207  AKT1; AKT serine/threonine kinase 1
            208  AKT2; AKT serine/threonine kinase 2
            10000  AKT3; AKT serine/threonine kinase 3
            572  BAD; BCL2 associated agonist of cell death
VARIANT     3082v1  HGF overexpression
METABOLITE  C05981  Phosphatidylinositol-3,4,5-trisphosphate
REFERENCE   PMID:16799620
  AUTHORS   Breuhahn K, Longerich T, Schirmacher P
  TITLE     Dysregulation of growth factor signaling in human hepatocellular carcinoma.
  JOURNAL   Oncogene 25:3787-800 (2006)
            DOI:10.1038/sj.onc.1209556
REFERENCE   PMID:25841916
  AUTHORS   Harding JJ, Abou-Alfa GK
  TITLE     Systemic therapy for hepatocellular carcinoma.
  JOURNAL   Chin Clin Oncol 2:37 (2013)
            DOI:10.3978/j.issn.2304-3865.2013.07.06
REFERENCE   PMID:24959084
  AUTHORS   Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ
  TITLE     The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.
  JOURNAL   Onco Targets Ther 7:969-83 (2014)
            DOI:10.2147/OTT.S40241
REFERENCE   PMID:27471710
  AUTHORS   Lee D, Sung ES, Ahn JH, An S, Huh J, You WK
  TITLE     Development of antibody-based c-Met inhibitors for targeted cancer therapy.
  JOURNAL   Immunotargets Ther 4:35-44 (2015)
            DOI:10.2147/ITT.S37409
///
